drugset / Trial / NCT05771480
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
NaSingle-groupOpen-labelTreatment
Summary
A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC.
Timeline
- Start
- 2023-08-16
- Primary completion
- 2025-10-02
- Completion
- 2026-09-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | S-1 | Small molecule | — | — |